Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.

Tamara Y MilderSophie Lena StockerDorit Samocha-BonetRichard O DayJerry R Greenfield

Published in: European journal of clinical pharmacology (2019)

Despite minimal glycaemic benefits in patients with type 2 diabetes and stage 3 CKD, the cardiovascular and renal benefits of these agents are preserved in this group of patients. Whether these agents have cardiovascular and renal benefits in patients with stage 4 CKD and patients with non-diabetic CKD needs further research.

Keyphrases

chronic kidney disease
type diabetes
end stage renal disease
ejection fraction
cardiovascular disease
prognostic factors
glycemic control
patient reported outcomes
wound healing